Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Endocrine Disorders
Published in: BMC Endocrine Disorders 1/2012

Open Access 01-12-2012 | Research article

The association of hypertriglyceridemia with cardiovascular events and pancreatitis: a systematic review and meta-analysis

Authors: M Hassan Murad, Ahmad Hazem, Fernando Coto-Yglesias, Svitlana Dzyubak, Shabnum Gupta, Irina Bancos, Melanie A Lane, Patricia J Erwin, Lars Berglund, Tarig Elraiyah, Victor M Montori

Published in: BMC Endocrine Disorders | Issue 1/2012

Login to get access

Abstract

Background

Hypertriglyceridemia may be associated with important complications. The aim of this study is to estimate the magnitude of association and quality of supporting evidence linking hypertriglyceridemia to cardiovascular events and pancreatitis.

Methods

We conducted a systematic review of multiple electronic bibliographic databases and subsequent meta-analysis using a random effects model. Studies eligible for this review followed patients longitudinally and evaluated quantitatively the association of fasting hypertriglyceridemia with the outcomes of interest. Reviewers working independently and in duplicate reviewed studies and extracted data.

Results

35 studies provided data sufficient for meta-analysis. The quality of these observational studies was moderate to low with fair level of multivariable adjustments and adequate exposure and outcome ascertainment. Fasting hypertriglyceridemia was significantly associated with cardiovascular death (odds ratios (OR) 1.80; 95% confidence interval (CI) 1.31-2.49), cardiovascular events (OR, 1.37; 95% CI, 1.23-1.53), myocardial infarction (OR, 1.31; 95% CI, 1.15-1.49), and pancreatitis (OR, 3.96; 95% CI, 1.27-12.34, in one study only). The association with all-cause mortality was not statistically significant.

Conclusions

The current evidence suggests that fasting hypertriglyceridemia is associated with increased risk of cardiovascular death, MI, cardiovascular events, and possibly acute pancreatitis.
Précis: hypertriglyceridemia is associated with increased risk of cardiovascular death, MI, cardiovascular events, and possibly acute pancreatitis
Appendix
Available only for authorised users
Literature
1.
Ford ES, Li C, Zhao G, Pearson WS, Mokdad AH: Hypertriglyceridemia and its pharmacologic treatment among US adults. Arch Intern Med. 2009, 169 (6): 572-578. 10.1001/archinternmed.2008.599.CrossRefPubMed
2.
Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, Boekholdt SM, Khaw KT, Gudnason V: Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007, 115 (4): 450-458. 10.1161/CIRCULATIONAHA.106.637793.CrossRefPubMed
3.
Hokanson JE, Austin MA: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996, 3 (2): 213-219. 10.1097/00043798-199604000-00014.CrossRefPubMed
4.
Patel A, Barzi F, Jamrozik K, Lam TH, Ueshima H, Whitlock G, Woodward M: Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation. 2004, 110 (17): 2678-2686.CrossRefPubMed
5.
Toskes PP: Hyperlipidemic pancreatitis. Gastroenterol Clin North Am. 1990, 19 (4): 783-791.PubMed
6.
Brunzell JD, Schrott HG: The interaction of familial and secondary causes of hypertriglyceridemia: role in pancreatitis. Trans Assoc Am Physicians. 1973, 86: 245-254.PubMed
7.
Familial lipoprotein lipase deficiency, ApoC-II deficiency, and hepatic lipase deficiency. The Metabolic Basis of Inherited Disease. Edited by: Scriver C, Beaudet A, Sly W, Valle D, Brunzell J, Deeb SI. 2001, New York: McGraw-Hill, 2789-2816. 8
8.
Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009, 6 (7): e1000097-10.1371/journal.pmed.1000097.CrossRefPubMedPubMedCentral
9.
Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute.
10.
Swiglo BA, Murad MH, Schunemann HJ, Kunz R, Vigersky RA, Guyatt GH, Montori VM: A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab. 2008, 93 (3): 666-673.CrossRefPubMed
11.
DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials. 1986, 7 (3): 177-188. 10.1016/0197-2456(86)90046-2.CrossRefPubMed
12.
Egger M, Davey Smith G, Schneider M, Minder Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997, 315 (7109): 629-634. 10.1136/bmj.315.7109.629.CrossRefPubMedPubMedCentral
13.
Acarturk E, Cayli M, Akpinar O, Attila G, Demir M: Relation between age and gender differences in plasma triglyceride concentrations and coronary artery disease in Southern Turkey. Clin Chim Acta. 2004, 339 (1-2): 123-128. 10.1016/j.cccn.2003.10.001.CrossRefPubMed
14.
Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM: Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007, 298 (3): 309-316. 10.1001/jama.298.3.309.CrossRefPubMed
15.
Barrett-Connor E, Khaw KT: Borderline fasting hypertriglyceridemia: absence of excess risk of all-cause and cardiovascular disease mortality in healthy men without hypercholesterolemia. Prev Med. 1987, 16 (1): 1-8. 10.1016/0091-7435(87)90001-6.CrossRefPubMed
16.
Bass KM, Newschaffer CJ, Klag MJ, Bush TL: Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med. 1993, 153 (19): 2209-2216. 10.1001/archinte.1993.00410190045006.CrossRefPubMed
17.
Bonaventure A, Kurth T, Pico F, Barberger-Gateau P, Ritchie K, Stapf C, Tzourio C: Triglycerides and risk of hemorrhagic stroke vs. ischemic vascular events: the three-city study. Atherosclerosis. 2010, 210 (1): 243-248. 10.1016/j.atherosclerosis.2009.10.043.CrossRefPubMed
18.
Carlson LA, Rosenhamer G: Reduction of mortality in the Stockholm ischaemic heart disease secondary prevention study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 1988, 223 (5): 405-418.CrossRefPubMed
19.
Chan WB, Tong PC, Chow CC, So WY, Ng MC, Ma RC, Osaki R, Cockram CS, Chan JC: Triglyceride predicts cardiovascular mortality and its relationship with glycaemia and obesity in Chinese type 2 diabetic patients. Diabetes Metab Res Rev. 2005, 21 (2): 183-188. 10.1002/dmrr.497.CrossRefPubMed
20.
Chester M, Chen L, Kaski JC: Identification of patients at high risk for adverse coronary events while awaiting routine coronary angioplasty. Br Heart J. 1995, 73 (3): 216-222. 10.1136/hrt.73.3.216.CrossRefPubMedPubMedCentral
21.
Czernichow S, Bruckert E, Bertrais S, Galan P, Hercberg S, Oppert JM: Hypertriglyceridemic waist and 7.5-year prospective risk of cardiovascular disease in asymptomatic middle-aged men. Int J Obes (Lond). 2007, 31 (5): 791-796.
22.
Drexel H, Aczel S, Marte T, Benzer W, Langer P, Moll W, Saely CH: Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol?. Diabetes Care. 2005, 28 (1): 101-107. 10.2337/diacare.28.1.101.CrossRefPubMed
23.
Eberly LE, Stamler J, Neaton JD: Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Arch Intern Med. 2003, 163 (9): 1077-1083. 10.1001/archinte.163.9.1077.CrossRefPubMed
24.
Egger M, Smith GD, Pfluger D, Altpeter E, Elwood PC: Triglyceride as a risk factor for ischaemic heart disease in British men: effect of adjusting for measurement error. Atherosclerosis. 1999, 143 (2): 275-284. 10.1016/S0021-9150(98)00300-1.CrossRefPubMed
25.
Ellingsen I, Hjermann I, Abdelnoor M, Hjerkinn EM, Tonstad S: Dietary and antismoking advice and ischemic heart disease mortality in men with normal or high fasting triacylglycerol concentrations: a 23-y follow-up study. Am J Clin Nutr. 2003, 78 (5): 935-940.PubMed
26.
Gaziano JM, Hennekens CH, O'Donnell CJ, Breslow JL, Buring JE: Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation. 1997, 96 (8): 2520-2525.CrossRefPubMed
27.
Goldberg RJ, Urowitz MB, Ibanez D, Nikpour M, Gladman DD: Risk factors for development of coronary artery disease in women with systemic lupus erythematosus. J Rheumatol. 2009, 36 (11): 2454-2461. 10.3899/jrheum.090011.CrossRefPubMed
28.
Habib AN, Baird BC, Leypoldt JK, Cheung AK, Goldfarb-Rumyantzev AS: The association of lipid levels with mortality in patients on chronic peritoneal dialysis. Nephrol Dial Transplant. 2006, 21 (10): 2881-2892. 10.1093/ndt/gfl272.CrossRefPubMed
29.
Haim M, Benderly M, Brunner D, Behar S, Graff E, Reicher-Reiss H, Goldbourt U: Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) registry. Circulation. 1999, 100 (5): 475-482.CrossRefPubMed
30.
Hoogeveen RC, Gambhir JK, Gambhir DS, Kimball KT, Ghazzaly K, Gaubatz JW, Vaduganathan M, Rao RS, Koschinsky M, Morrisett JD: Evaluation of Lp[a] and other independent risk factors for CHD in Asian Indians and their USA counterparts. J Lipid Res. 2001, 42 (4): 631-638.PubMed
31.
Jonsdottir LS, Sigfusson N, Guonason V, Sigvaldason H, Thorgeirsson G: Do lipids, blood pressure, diabetes, and smoking confer equal risk of myocardial infarction in women as in men? The Reykjavik study. J Cardiovasc Risk. 2002, 9 (2): 67-76. 10.1097/00043798-200204000-00001.CrossRefPubMed
32.
Lamarche B, Despres JP, Moorjani S, Cantin B, Dagenais GR, Lupien PJ: Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Quebec Cardiovascular study). Am J Cardiol. 1995, 75 (17): 1189-1195. 10.1016/S0002-9149(99)80760-7.CrossRefPubMed
33.
Lloret Linares C, Pelletier AL, Czernichow S, Vergnaud AC, Bonnefont-Rousselot D, Levy P, Ruszniewski P, Bruckert E: Acute pancreatitis in a cohort of 129 patients referred for severe hypertriglyceridemia. Pancreas. 2008, 37 (1): 12-13.
34.
Lu W, Resnick HE, Jablonski KA, Jones KL, Jain AK, Howard WMJ, Robbins DC, Howard BV: Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: The strong heart study. Diabetes Care. 2003, 26 (1): 16-23. 10.2337/diacare.26.1.16.CrossRefPubMed
35.
Malone DC, Boudreau DM, Nichols GA, Raebel MA, Fishman PA, Feldstein AC, Ben-Joseph RH, Okamoto LJ, Boscoe AN, Magid DJ: Association of cardiometabolic risk factors and prevalent cardiovascular events. Metab Syndr Relat Disord. 2009, 7 (6): 585-593. 10.1089/met.2009.0033.CrossRefPubMed
36.
Mazza A, Tikhonoff V, Schiavon L, Casiglia E: Triglycerides + high-density-lipoprotein-cholesterol dyslipidaemia, a coronary risk factor in elderly women: the CArdiovascular STudy in the ELderly. Intern Med J. 2005, 35 (10): 604-610. 10.1111/j.1445-5994.2005.00940.x.CrossRefPubMed
37.
Mora S, Rifai N, Buring JE, Ridker PM: Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation. 2008, 118 (10): 993-1001. 10.1161/CIRCULATIONAHA.108.777334.CrossRefPubMedPubMedCentral
38.
Noda H, Maruyama K, Iso H, Dohi S, Terai T, Fujioka S, Goto K, Horie S, Nakano S, Hirobe K: Prediction of myocardial infarction using coronary risk scores among Japanese male workers: 3M study. J Atheroscler Thromb. 2010, 17 (5): 452-459. 10.5551/jat.3277.CrossRefPubMed
39.
Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999, 341 (6): 410-418. 10.1056/NEJM199908053410604.CrossRefPubMed
40.
Samuelsson O, Hedner T, Persson B, Andersson O, Berglund G, Wilhelmesen L: The role of diabetes mellitus and hypertriglyceridaemia as coronary risk factors in treated hypertension: 15 years of follow-up of antihypertensive treatment in middle-aged men in the Primary Prevention Trial in Goteborg, Sweden. J Intern Med. 1994, 235 (3): 217-227. 10.1111/j.1365-2796.1994.tb01063.x.CrossRefPubMed
41.
Schupf N, Costa R, Luchsinger J, Tang MX, Lee JH, Mayeux R: Relationship between plasma lipids and all-cause mortality in nondemented elderly. J Am Geriatr Soc. 2005, 53 (2): 219-226. 10.1111/j.1532-5415.2005.53106.x.CrossRefPubMed
42.
Sprecher DL, Pearce GL, Park EM, Pashkow FJ, Hoogwerf BJ: Preoperative triglycerides predict post-coronary artery bypass graft survival in diabetic patients: a sex analysis. Diabetes Care. 2000, 23 (11): 1648-1653. 10.2337/diacare.23.11.1648.CrossRefPubMed
43.
Tanko LB, Bagger YZ, Qin G, Alexandersen P, Larsen PJ, Christiansen C: Enlarged waist combined with elevated triglycerides is a strong predictor of accelerated atherogenesis and related cardiovascular mortality in postmenopausal women. Circulation. 2005, 111 (15): 1883-1890. 10.1161/01.CIR.0000161801.65408.8D.CrossRefPubMed
44.
Tsai SP, Wen CP, Chan HT, Chiang PH, Tsai MK, Cheng TY: The effects of pre-disease risk factors within metabolic syndrome on all-cause and cardiovascular disease mortality. Diabetes Res Clin Pract. 2008, 82 (1): 148-156. 10.1016/j.diabres.2008.07.016.CrossRefPubMed
45.
Upmeier E, Lavonius S, Lehtonen A, Viitanen M, Isoaho H, Arve S: Serum lipids and their association with mortality in the elderly: A prospective cohort study. Aging Clin Exp Res. 2009, 21 (6): 424-430.CrossRefPubMed
46.
Valdivielso P, Sanchez-Chaparro MA, Calvo-Bonacho E, Cabrera-Sierra M, Sainz-Gutierrez JC, Fernandez-Labandera C, Fernandez-Meseguer A, Quevedo-Aguado L, Moraga MR, Galvez-Moraleda A: Association of moderate and severe hypertriglyceridemia with obesity, diabetes mellitus and vascular disease in the Spanish working population: results of the ICARIA study. Atherosclerosis. 2009, 207 (2): 573-578. 10.1016/j.atherosclerosis.2009.05.024.CrossRefPubMed
47.
Weir CJ, Sattar N, Walters MR, Lees KR: Low triglyceride, not low cholesterol concentration, independently predicts poor outcome following acute stroke. Cerebrovasc Dis. 2003, 16 (1): 76-82. 10.1159/000070119.CrossRefPubMed
48.
Furukawa TA, Watanabe N, Omori IM, Montori VM, Guyatt GH: Association between unreported outcomes and effect size estimates in Cochrane meta-analyses. JAMA. 2007, 297 (5): 468-470.CrossRefPubMed
49.
Labreuche J, Deplanque D, Touboul PJ, Bruckert E, Amarenco P: Association between change in plasma triglyceride levels and risk of stroke and carotid atherosclerosis: systematic review and meta-regression analysis. Atherosclerosis. 2010, 212 (1): 9-15. 10.1016/j.atherosclerosis.2010.02.011.CrossRefPubMed
50.
Gandhi GY, Murad MH, Fujiyoshi A, Mullan RJ, Flynn DN, Elamin MB, Swiglo BA, Isley WL, Guyatt GH, Montori VM: Patient-important outcomes in registered diabetes trials. JAMA. 2008, 299 (21): 2543-2549. 10.1001/jama.299.21.2543.CrossRefPubMed
51.
Bruckert E, Labreuche J, Deplanque D, Touboul PJ, Amarenco P: Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis. J Cardiovasc Pharmacol. 2011, 57 (2): 267-272. 10.1097/FJC.0b013e318202709f.CrossRefPubMed
52.
Loomba RS, Arora R: Prevention of cardiovascular disease utilizing fibrates-a pooled meta-analysis. Am J Ther. 2010, 17 (6): e182-e188. 10.1097/MJT.0b013e3181dcf72b.CrossRefPubMed
53.
Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, Grobbee DE, Cass A, Chalmers J, Perkovic V: Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010, 375 (9729): 1875-1884. 10.1016/S0140-6736(10)60656-3.CrossRefPubMed
54.
Lee M, Saver JL, Towfighi A, Chow J, Ovbiagele B: Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: A meta-analysis. Atherosclerosis. 2011
55.
Bruckert E, Labreuche J, Amarenco P: Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis. 2010, 210 (2): 353-361. 10.1016/j.atherosclerosis.2009.12.023.CrossRefPubMed
56.
Duggal JK, Singh M, Attri N, Singh PP, Ahmed N, Pahwa S, Molnar J, Singh S, Khosla S, Arora R: Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease. J Cardiovasc Pharmacol Ther. 2010, 15 (2): 158-166. 10.1177/1074248410361337.CrossRefPubMed
57.
Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, Hubbard L, Esser BA, Lovato JF, Perdue LH: Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010, 363 (3): 233-244.CrossRefPubMed
58.
AIM-HIGH Investigators: The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH). Am Heart J. 2011, 161 (3): 471-477. e472CrossRef
Metadata
Title
The association of hypertriglyceridemia with cardiovascular events and pancreatitis: a systematic review and meta-analysis
Authors
M Hassan Murad
Ahmad Hazem
Fernando Coto-Yglesias
Svitlana Dzyubak
Shabnum Gupta
Irina Bancos
Melanie A Lane
Patricia J Erwin
Lars Berglund
Tarig Elraiyah
Victor M Montori
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2012
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/1472-6823-12-2

Other articles of this Issue 1/2012

BMC Endocrine Disorders 1/2012 Go to the issue

Research article

Diabetes related knowledge among residents and nurses: a multicenter study in Karachi, Pakistan

Case report

A case report: Giant cystic parathyroid adenoma presenting with parathyroid crisis after Vitamin D replacement

Research article

Assessment of endogenous insulin secretion in insulin treated diabetes predicts postprandial glucose and treatment response to prandial insulin

Research article

No effect modification of serum bilirubin or coffee consumption on the association of gamma-glutamyltransferase with glycated hemoglobin in a cross-sectional study of Japanese men and women

Research article

Insulin analogues dosing and costs - comparing real-life daily doses of insulin detemir and insulin glargine in type 2 diabetes patients

Research article

Prevalence of diabetes mellitus among non institutionalized elderly in Monastir City
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits